# Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

> **NCT01456351** · PHASE3 · COMPLETED · sponsor: **University of Giessen** · enrollment: 230 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bendamustine plus Rituximab
- **DRUG:** Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w

## Key facts

- **NCT ID:** NCT01456351
- **Lead sponsor:** University of Giessen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2010-08
- **Final completion:** 2010-12
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456351, "Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01456351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*